What is it about?
YAP1 is possibly involved in the regulation of neuroendocrine differentiation of lung tumors. Loss of YAP1 correlated with strong expression of neuroendocrine markers. Loss of YAP1 is a predictor of chemothensitivity in high-grade neuroendocrine tumors.
Featured Image
Why is it important?
In this study, we report the potential of the loss of YAP1 as a clinical marker to predict neuroendocrine features and chemosensitivity. As far as we know, this study is the first to reveal the roles of YAP1 not only in cisplatin resistance but also in determination of neuroendocrine features of high-grade neuroendocrine tumors.
Perspectives
Immunohistochemically, 98% of SCLC and 60% of LCNEC were completely negative for YAP1, while only 3% of NSCLC were negative for YAP1. It has been controversial whether LCNECs are as chemosensitive as SCLCs or not. Our research indicated that the cases diagnosed as LCNEC contained two types: SCLC-phenotype sensitive to chemotherapy and NSCLC-phenotype resistant to chemotherapy. The loss of YAP1 defines a unique subset of high-grade neuroendocrine tumors, in other words, SCLC-phenotype, showing chemosensitivity. In addition, in this research, VMRC-LCD, established as adenocarcinoma cell line, turned out to be LCNCEC cell line showing loss of YAP1 and high level expressions of neuroendocrine markers.
Dr Daisuke Matsubara
Jichi Medical University
Read the Original
This page is a summary of: Loss ofYAP1defines neuroendocrine differentiation of lung tumors, Cancer Science, September 2016, Wiley,
DOI: 10.1111/cas.13013.
You can read the full text:
Contributors
The following have contributed to this page
